Form 8-K - Current report:
SEC Accession No. 0001837607-25-000015
Filing Date
2025-03-10
Accepted
2025-03-10 06:00:33
Documents
32
Period of Report
2025-03-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20250310x8k.htm   iXBRL 8-K 41651
2 EX-99 aeon-20250310xex99.htm EX-99 31414
3 GRAPHIC aeon-20250310xex99g001.jpg GRAPHIC 66728
4 GRAPHIC aeon-20250310xex99g002.jpg GRAPHIC 338816
5 GRAPHIC aeon-20250310xex99g003.jpg GRAPHIC 145007
6 GRAPHIC aeon-20250310xex99g004.jpg GRAPHIC 184685
7 GRAPHIC aeon-20250310xex99g005.jpg GRAPHIC 140524
8 GRAPHIC aeon-20250310xex99g006.jpg GRAPHIC 161992
9 GRAPHIC aeon-20250310xex99g007.jpg GRAPHIC 128473
10 GRAPHIC aeon-20250310xex99g008.jpg GRAPHIC 151181
11 GRAPHIC aeon-20250310xex99g009.jpg GRAPHIC 139786
12 GRAPHIC aeon-20250310xex99g010.jpg GRAPHIC 114159
13 GRAPHIC aeon-20250310xex99g011.jpg GRAPHIC 154452
14 GRAPHIC aeon-20250310xex99g012.jpg GRAPHIC 119611
15 GRAPHIC aeon-20250310xex99g013.jpg GRAPHIC 108871
16 GRAPHIC aeon-20250310xex99g014.jpg GRAPHIC 141050
17 GRAPHIC aeon-20250310xex99g015.jpg GRAPHIC 43983
18 GRAPHIC aeon-20250310xex99g016.jpg GRAPHIC 176402
19 GRAPHIC aeon-20250310xex99g017.jpg GRAPHIC 53541
  Complete submission text file 0001837607-25-000015.txt   3462107

Data Files

Seq Description Document Type Size
20 EX-101.SCH aeon-20250310.xsd EX-101.SCH 4041
21 EX-101.DEF aeon-20250310_def.xml EX-101.DEF 2866
22 EX-101.LAB aeon-20250310_lab.xml EX-101.LAB 17850
23 EX-101.PRE aeon-20250310_pre.xml EX-101.PRE 10672
34 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20250310x8k_htm.xml XML 5053
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 25721972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)